Grand Brilliance Group Holdings Valuation
Is 8372 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8372?
Other financial metrics that can be useful for relative valuation.
| What is 8372's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | HK$59.20m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.04x |
| Enterprise Value/EBITDA | 0.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 8372's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 39.7x | ||
1110 Kingworld Medicines Group | 8.7x | n/a | HK$348.6m |
2289 Charmacy Pharmaceutical | 37.7x | n/a | HK$766.8m |
1298 Yunnan Energy International | 106.9x | n/a | HK$275.4m |
6833 Sinco Pharmaceuticals Holdings | 5.6x | n/a | HK$772.5m |
8372 Grand Brilliance Group Holdings | 17.4x | n/a | HK$59.2m |
Price to Earnings Ratio vs Industry
How does 8372's PE Ratio compare vs other companies in the HK Healthcare Industry?
Price to Earnings Ratio vs Fair Ratio
What is 8372's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8372's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 8372 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?